Primary aldosteronism in a hispanic cohort: responses to mineralocorticoid receptor antagonism and remission in a case

Simple item page
dc.catalogadoryvc
dc.contributor.authorTapia Castillo, Alejandra
dc.contributor.authorVecchiola Cárdenas, Andrea Paola
dc.contributor.authorQuiñones, Paola
dc.contributor.authorBaudrand Biggs, Rene Felipe
dc.contributor.authorUslar Nawrath, Thomas Hermann
dc.contributor.authorDelgado García, José Frobel
dc.contributor.authorCarvajal Maldonado, Cristian Andrés
dc.contributor.authorFardella Bello, Carlos Enrique
dc.date.accessioned2025-03-10T13:11:55Z
dc.date.available2025-03-10T13:11:55Z
dc.date.issued2025
dc.description.abstractBackground: Primary aldosteronism (PA) is the main cause of secondary arterial hypertension. In this study, we present the medical treatment of Hispanic patients with PA followed for up to 5 years, highlighting the complete cure with pharmacological treatment in one of our patients. Methods: We studied 32 PA patients, followed every 6 months after starting MRA. A clinical response was the normalization of blood pressure (BP) in the absence of other antihypertensive drugs. The biochemical response was considered with normalization of potassium and renin. Responses to treatment were compared using the defined daily dose (DDD). The effect of MRA was evaluated in vitro. The HAC15 cells were cultured and stimulated with aldosterone and spironolactone for 24-72h, and the apoptotic cell death was measured. Results: At 12 months posttreatment with MRA, 68% of the patients had a total clinical response, and 67% had a total biochemical response. Response to MRA treatment reduced DDD by an average of 74%. Additionally, we observed one PA patients treated with spironolactone after three years, he presented a pharmacological cure with normalization of aldosterone and renin without treatment with spironolactone. The in vitro study shows that spironolactone increased early apoptosis in a 60% and late apoptosis in a 50%. Conclusion: These results suggest the importance of timely diagnosis of PA and specific treatment with MRA, especially in patients with a poor response to treatment. Moreover, remission of PA may occur in some patients after spironolactone treatment due to its suggestive role as an apoptotic agent.
dc.format.extent31 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1093/ajh/hpaf020
dc.identifier.eissn1941-7225
dc.identifier.urihttps://doi.org/10.1093/ajh/hpaf020
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/102454
dc.information.autorucEscuela de Medicina; Tapia Castillo Alejandra; 0000-0002-6081-1468; 1012854
dc.information.autorucEscuela de Medicina; Vecchiola Cardenas Andrea Paola; S/I; 123319
dc.information.autorucEscuela de Medicina; Baudrand Biggs Rene Felipe; 0000-0002-8655-4957; 1024
dc.information.autorucEscuela de Medicina; Uslar Nawrath Thomas Hermann; S/I; 187161
dc.information.autorucEscuela de Medicina; Delgado Garcia Jose Frobel; S/I; 218702
dc.information.autorucEscuela de Medicina; Carvajal Maldonado Cristian Andres; 0000-0002-0668-412X; 8586
dc.information.autorucEscuela de Medicina; Fardella Bello Carlos Enrique; 0000-0002-5500-4434; 66235
dc.language.isoen
dc.nota.accesoContenido parcial
dc.revistaAmerican Journal of Hypertension
dc.rightsacceso restringido
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titlePrimary aldosteronism in a hispanic cohort: responses to mineralocorticoid receptor antagonism and remission in a case
dc.typeartículo
sipa.codpersvinculados1012854
sipa.codpersvinculados123319
sipa.codpersvinculados1024
sipa.codpersvinculados187161
sipa.codpersvinculados218702
sipa.codpersvinculados8586
sipa.codpersvinculados66235
sipa.trazabilidadORCID;2025-03-03
Files
Collections
Artículos de revistas